680 related articles for article (PubMed ID: 25097804)
1. Trial Watch:: Oncolytic viruses for cancer therapy.
Pol J; Bloy N; Obrist F; Eggermont A; Galon J; Cremer I; Erbs P; Limacher JM; Preville X; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2014; 3():e28694. PubMed ID: 25097804
[TBL] [Abstract][Full Text] [Related]
2. Trial watch: Oncolytic viruses for cancer therapy.
Vacchelli E; Eggermont A; Sautès-Fridman C; Galon J; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2013 Jun; 2(6):e24612. PubMed ID: 23894720
[TBL] [Abstract][Full Text] [Related]
3. Trial Watch-Oncolytic viruses and cancer therapy.
Pol J; Buqué A; Aranda F; Bloy N; Cremer I; Eggermont A; Erbs P; Fucikova J; Galon J; Limacher JM; Preville X; Sautès-Fridman C; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2016 Feb; 5(2):e1117740. PubMed ID: 27057469
[TBL] [Abstract][Full Text] [Related]
4. Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches.
Ji Q; Wu Y; Albers A; Fang M; Qian X
Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145559
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
6. Immune System, Friend or Foe of Oncolytic Virotherapy?
Filley AC; Dey M
Front Oncol; 2017; 7():106. PubMed ID: 28589085
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
8. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
Pol JG; Lévesque S; Workenhe ST; Gujar S; Le Boeuf F; Clements DR; Fahrner JE; Fend L; Bell JC; Mossman KL; Fucikova J; Spisek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2018; 7(12):e1503032. PubMed ID: 30524901
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.
Taguchi S; Fukuhara H; Todo T
Jpn J Clin Oncol; 2019 Mar; 49(3):201-209. PubMed ID: 30462296
[TBL] [Abstract][Full Text] [Related]
10. The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies.
Ahn DH; Bekaii-Saab T
Biomedicines; 2017 Mar; 5(1):. PubMed ID: 28536353
[TBL] [Abstract][Full Text] [Related]
11. Talimogene laherparepvec: First in class oncolytic virotherapy.
Conry RM; Westbrook B; McKee S; Norwood TG
Hum Vaccin Immunother; 2018 Apr; 14(4):839-846. PubMed ID: 29420123
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses.
Hadryś A; Sochanik A; McFadden G; Jazowiecka-Rakus J
Eur J Pharmacol; 2020 May; 874():172991. PubMed ID: 32044323
[TBL] [Abstract][Full Text] [Related]
13. Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.
Park GT; Choi KC
Oncotarget; 2016 Sep; 7(36):58684-58695. PubMed ID: 27494901
[TBL] [Abstract][Full Text] [Related]
14. Employing RNA viruses to fight cancer: novel insights into oncolytic virotherapy.
Masemann D; Boergeling Y; Ludwig S
Biol Chem; 2017 Jul; 398(8):891-909. PubMed ID: 28441138
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Virotherapy for Cancer: Clinical Experience.
Chaurasiya S; Fong Y; Warner SG
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33924556
[TBL] [Abstract][Full Text] [Related]
16. Radiovirotherapy: principles and prospects in oncology.
Touchefeu Y; Franken P; Harrington KJ
Curr Pharm Des; 2012; 18(22):3313-20. PubMed ID: 22397732
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.
Zheng M; Huang J; Tong A; Yang H
Mol Ther Oncolytics; 2019 Dec; 15():234-247. PubMed ID: 31872046
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
[TBL] [Abstract][Full Text] [Related]
19. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]